Latest news with #JohnMackey
Business Wire
29-07-2025
- Business
- Business Wire
Modella AI and illumiSonics Announce Successful Research Compatibility Between Virtual H&E Imaging and Generative AI-Powered Pathology Diagnostic Platform
BOSTON & WATERLOO, Ontario--(BUSINESS WIRE)-- Modella AI, a leader in generative and agentic artificial intelligence for biomedicine, and illumiSonics Inc., a leader in label-free optical imaging and computational pathology, today announced successful research demonstrating compatibility between illumiSonics' research-use only Multi-Laser Imaging (MLI™) system and Modella AI's research-use only PathChat™ DX platform, which has been granted a Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). These novel study findings support the potential of an end-to-end, fully digital pathology workflow—from label-free tissue imaging to AI-enabled diagnostic interpretation—conducted without chemical staining or tissue damage. 'Enabling diagnostic-grade AI inference from label-free slides is a transformative step forward and advances the vision of digital-first pathology workflows that preserve tissue integrity and can streamline diagnostic throughput,' said Jill Stefanelli, CEO Share In the joint study, the illumiSonics' MLI system produced virtual H&E (Hematoxylin and Eosin-like) images from unstained skin tissue resections showing various malignant features. These de-identified images were analyzed using the PathChat DX platform, which had no prior exposure or training on any form of virtual histology. Diagnostic interpretations from the PathChat DX platform were compared to consensus reads by eight board-certified pathologists with expertise in dermatologic pathology who reviewed both the virtual images and matched chemical H&E slides. Concordance between PathChat DX and expert pathologists was extremely high, demonstrating the feasibility of a fully digital, AI-assisted workflow from unstained whole slides to clinical diagnosis. 'Enabling diagnostic-grade AI inference from label-free slides is a transformative step forward and advances the vision of digital-first pathology workflows that preserve tissue integrity and can streamline diagnostic throughput,' said Jill Stefanelli, CEO of Modella AI. 'While PathChat DX remains research-use only, its compatibility with diverse imaging outputs like those from the MLI™ platform reinforces the adaptability and promise of our generative and agentic AI platform.' Results of this novel research study underscore the advantages of label-free imaging over chemical staining that is used in traditional pathology workflows, which is irreversible, labor-intensive, and can interfere with downstream molecular testing. illumiSonics' MLI platform produces high-resolution virtual H&E images without dyes or tissue destruction, highlighting its potential value in clinical settings that prioritize tissue preservation for additional molecular testing. and precision medicine applications. 'illumiSonics is proud to collaborate on research that explores new possibilities for stain-free, digital pathology,' said John Mackey, CEO of illumiSonics Inc. 'Our MLI system is designed to generate morphologically rich, label-free images suitable for computational analysis in research environments. This compatibility study with PathChat DX demonstrates the potential for next-generation virtual histology to drive fully automated diagnostic pipelines, unlocking new possibilities in clinical diagnosis, precision medicine, and translational research.' About Modella AI Modella AI is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. Its mission is to enhance diagnostic accuracy and access through intelligent, scalable platforms that empower healthcare providers. Visit for more information. About illumiSonics Inc. illumiSonics Inc. is a biomedical technology company developing non-destructive, label-free imaging platforms for high-content tissue analysis. Its patented technology platform enables high-resolution optical sectioning and digital reconstruction of tissue architecture without the need for dyes, stains, or tissue damage—unlocking unprecedented flexibility for clinical diagnostics, research, and biopharmaceutical development. Learn more at Disclaimer: PathChat™ DX and the illumiSonics MLI™ platform are research-use only devices and are not commercially available outside of research use. The FDA Breakthrough Device Designation for PathChat DX does not imply FDA clearance or approval. This press release contains forward-looking statements based on current assumptions and forecasts. Modella AI and illumiSonics assume no obligation to update these statements to reflect future events or developments.
National Post
29-07-2025
- Health
- National Post
Modella AI and illumiSonics Announce Successful Research Compatibility Between Virtual H&E Imaging and Generative AI-Powered Pathology Diagnostic Platform
Article content BOSTON & WATERLOO, Ontario — Modella AI, a leader in generative and agentic artificial intelligence for biomedicine, and illumiSonics Inc., a leader in label-free optical imaging and computational pathology, today announced successful research demonstrating compatibility between illumiSonics' research-use only Multi-Laser Imaging (MLI™) system and Modella AI's research-use only PathChat™ DX platform, which has been granted a Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). These novel study findings support the potential of an end-to-end, fully digital pathology workflow—from label-free tissue imaging to AI-enabled diagnostic interpretation—conducted without chemical staining or tissue damage. Article content In the joint study, the illumiSonics' MLI system produced virtual H&E (Hematoxylin and Eosin-like) images from unstained skin tissue resections showing various malignant features. These de-identified images were analyzed using the PathChat DX platform, which had no prior exposure or training on any form of virtual histology. Diagnostic interpretations from the PathChat DX platform were compared to consensus reads by eight board-certified pathologists with expertise in dermatologic pathology who reviewed both the virtual images and matched chemical H&E slides. Concordance between PathChat DX and expert pathologists was extremely high, demonstrating the feasibility of a fully digital, AI-assisted workflow from unstained whole slides to clinical diagnosis. Article content 'Enabling diagnostic-grade AI inference from label-free slides is a transformative step forward and advances the vision of digital-first pathology workflows that preserve tissue integrity and can streamline diagnostic throughput,' said Jill Stefanelli, CEO of Modella AI. 'While PathChat DX remains research-use only, its compatibility with diverse imaging outputs like those from the MLI™ platform reinforces the adaptability and promise of our generative and agentic AI platform.' Article content Results of this novel research study underscore the advantages of label-free imaging over chemical staining that is used in traditional pathology workflows, which is irreversible, labor-intensive, and can interfere with downstream molecular testing. illumiSonics' MLI platform produces high-resolution virtual H&E images without dyes or tissue destruction, highlighting its potential value in clinical settings that prioritize tissue preservation for additional molecular testing. and precision medicine applications. Article content 'illumiSonics is proud to collaborate on research that explores new possibilities for stain-free, digital pathology,' said John Mackey, CEO of illumiSonics Inc. 'Our MLI system is designed to generate morphologically rich, label-free images suitable for computational analysis in research environments. This compatibility study with PathChat DX demonstrates the potential for next-generation virtual histology to drive fully automated diagnostic pipelines, unlocking new possibilities in clinical diagnosis, precision medicine, and translational research.' Article content About Modella AI Article content Modella AI is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. Its mission is to enhance diagnostic accuracy and access through intelligent, scalable platforms that empower healthcare providers. Visit for more information. Article content About illumiSonics Inc. Article content illumiSonics Inc. is a biomedical technology company developing non-destructive, label-free imaging platforms for high-content tissue analysis. Its patented technology platform enables high-resolution optical sectioning and digital reconstruction of tissue architecture without the need for dyes, stains, or tissue damage—unlocking unprecedented flexibility for clinical diagnostics, research, and biopharmaceutical development. Learn more at Article content PathChat™ DX and the illumiSonics MLI™ platform are research-use only devices and are not commercially available outside of research use. The FDA Breakthrough Device Designation for PathChat DX does not imply FDA clearance or approval. This press release contains forward-looking statements based on current assumptions and forecasts. Modella AI and illumiSonics assume no obligation to update these statements to reflect future events or developments. Article content Article content Article content Article content Article content
Yahoo
29-07-2025
- Business
- Yahoo
Modella AI and illumiSonics Announce Successful Research Compatibility Between Virtual H&E Imaging and Generative AI-Powered Pathology Diagnostic Platform
BOSTON & WATERLOO, Ontario, July 29, 2025--(BUSINESS WIRE)--Modella AI, a leader in generative and agentic artificial intelligence for biomedicine, and illumiSonics Inc., a leader in label-free optical imaging and computational pathology, today announced successful research demonstrating compatibility between illumiSonics' research-use only Multi-Laser Imaging (MLI™) system and Modella AI's research-use only PathChat™ DX platform, which has been granted a Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). These novel study findings support the potential of an end-to-end, fully digital pathology workflow—from label-free tissue imaging to AI-enabled diagnostic interpretation—conducted without chemical staining or tissue damage. In the joint study, the illumiSonics' MLI system produced virtual H&E (Hematoxylin and Eosin-like) images from unstained skin tissue resections showing various malignant features. These de-identified images were analyzed using the PathChat DX platform, which had no prior exposure or training on any form of virtual histology. Diagnostic interpretations from the PathChat DX platform were compared to consensus reads by eight board-certified pathologists with expertise in dermatologic pathology who reviewed both the virtual images and matched chemical H&E slides. Concordance between PathChat DX and expert pathologists was extremely high, demonstrating the feasibility of a fully digital, AI-assisted workflow from unstained whole slides to clinical diagnosis. "Enabling diagnostic-grade AI inference from label-free slides is a transformative step forward and advances the vision of digital-first pathology workflows that preserve tissue integrity and can streamline diagnostic throughput," said Jill Stefanelli, CEO of Modella AI. "While PathChat DX remains research-use only, its compatibility with diverse imaging outputs like those from the MLI™ platform reinforces the adaptability and promise of our generative and agentic AI platform." Results of this novel research study underscore the advantages of label-free imaging over chemical staining that is used in traditional pathology workflows, which is irreversible, labor-intensive, and can interfere with downstream molecular testing. illumiSonics' MLI platform produces high-resolution virtual H&E images without dyes or tissue destruction, highlighting its potential value in clinical settings that prioritize tissue preservation for additional molecular testing. and precision medicine applications. "illumiSonics is proud to collaborate on research that explores new possibilities for stain-free, digital pathology," said John Mackey, CEO of illumiSonics Inc. "Our MLI system is designed to generate morphologically rich, label-free images suitable for computational analysis in research environments. This compatibility study with PathChat DX demonstrates the potential for next-generation virtual histology to drive fully automated diagnostic pipelines, unlocking new possibilities in clinical diagnosis, precision medicine, and translational research." About Modella AI Modella AI is a Boston-based biomedical AI company dedicated to advancing healthcare through the development of cutting-edge generative and agentic AI technologies. Its mission is to enhance diagnostic accuracy and access through intelligent, scalable platforms that empower healthcare providers. Visit for more information. About illumiSonics Inc. illumiSonics Inc. is a biomedical technology company developing non-destructive, label-free imaging platforms for high-content tissue analysis. Its patented technology platform enables high-resolution optical sectioning and digital reconstruction of tissue architecture without the need for dyes, stains, or tissue damage—unlocking unprecedented flexibility for clinical diagnostics, research, and biopharmaceutical development. Learn more at Disclaimer: PathChat™ DX and the illumiSonics MLI™ platform are research-use only devices and are not commercially available outside of research use. The FDA Breakthrough Device Designation for PathChat DX does not imply FDA clearance or approval. This press release contains forward-looking statements based on current assumptions and forecasts. Modella AI and illumiSonics assume no obligation to update these statements to reflect future events or developments. View source version on Contacts press@
Globe and Mail
20-07-2025
- Business
- Globe and Mail
4 Reasons to Buy Palantir Stock Like There's No Tomorrow
Palantir (NASDAQ: PLTR) stock is up over 420% in just one year -- but many investors still don't understand what's fueling the surge. From government contracts and AI dominance to explosive commercial growth, this video breaks down the real reasons Palantir might just be getting started. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Stock prices used were the market prices of July 14, 2025. The video was published on July 18, 2025. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. *Stock Advisor returns as of July 15, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Rick Orford has positions in Amazon and Meta Platforms. The Motley Fool has positions in and recommends Amazon, Meta Platforms, and Palantir Technologies. The Motley Fool has a disclosure policy.
Irish Times
26-06-2025
- Irish Times
‘He was perfect, a one-off': Pensioner killed in London is remembered as proud Kilkenny man
John Mackey, the 87-year-old Irish man who died after being attacked while walking home from grocery shopping in north London, will be remembered as a man 'with a twinkle in his eye', his funeral heard on Thursday. Originally from Callan, Co Kilkenny, Mr Mackey had been living in London since the age of 19. He was running errands on the afternoon of May 6th when he was allegedly assaulted near his home close to Goodchild Road. He suffered serious head injuries and died in hospital two days later. On Thursday, his remains were carried into the Church of the Assumption in his south Kilkenny hometown by six pallbearers, a number of whom were his nephews. READ MORE A guard of honour was provided by retired Irish UN peacekeepers, as one of Mr Mackey's brothers is a former member. His coffin was adorned with two flags, representing his beloved Arsenal Football Club and the county colours of Kilkenny. There was also a photograph of Mr Mackey wearing his trilby hat. Mementos of his life were brought to the altar by members of his extended family. Parish priest Fr William Dalton said Mr Mackey's trilby exemplified how he had always been a dapper dresser with a love of good clothes. The Callan flag, and a book on the town by John Fitzgerald that had brought Mr Mackey memories of his beloved county, were included, as well as a photo of him with two nephews and his brother Christy. John Mackey worked as a postman in Callan before moving to England where he became a loyal part of the Irish community, his funeral heard. Photograph: Sarah Murphy There were his rosary beads which were said to have helped him through his long, happy and fruitful life. Fr Dalton told mourners they were there 'to say farewell as a person with faith which helped him through a long and happy life'. 'When we think of the Mackeys in the 1930s and 1940s, a family of 11 children, six boys and five girls, a very Catholic family. Their mother died when the eldest of the children was 15 and to make matters worse their father was taken from them. It was a time when there were no social services and no children's allowance, but they were able to survive,' he said. He recalled how their sister Kitty reared the children, enabling them to live together as a family. 'Most of them in time went to England with some returning.' Mr Mackey, he said, had worked as a postman in Callan before moving to England in 1956 where he worked for a pharmaceutical company. 'There he would spend his life and would become immersed in the culture [and] integrated into society. He became a devout Arsenal fan and a loyal part of the Irish community there. Part of him will always be with us, even though there is a void, the memories of him will always be with us.' In her eulogy, his sister Betty recalled how her brother had been well-known in Callan before his departure. Pat, the eldest of Mr Mackey's 22 nieces and nephews remembered 'the perfect uncle' who 'always had a twinkle in his eye, always smelling of lovely aftershave'. 'He was a new age man, many [women] had tried to get him to the altar but failed. One woman almost got him there, but John forgot his wallet on Christmas Eve at 4.55pm and the jewellers were closing,' she said. She recalled spending time with him in Finsbury Park, trying to get him to eat Chinese food. 'But, no, he had to have his fry with chips. We all remember such happy times, he was a one-off. We are so incredibly lucky to have had him as our uncle.' Mr Mackey was one of 11 siblings and is survived by four. He was buried in Kilbride Cemetery. A man has been arrested and charged with Mr Mackey's murder and with robbery.
